Author Archives | BeckyShadle
BeckyShadle - who has written 34 posts on FavStocks.
A business savvy Seattle native who has run a successful Seattle based business for 9 years. Becky likes to keep a close watch on the Biotechnolgy sector and maintains long term hold positions (20% portfolio) and enjoys the high risks and the lucrative returns.
She likes to keep watch on companies in all stages of FDA drug approval. Combining key information with an unemotional view she hopes that you might be able to spot some big opportunities in the biotech sector.
Amgen faces FDA delays (NASDAQ:AMGN)
On Monday morning Amgen Inc made an announcement that the Food and Drug Administration has issued them a Complete Response letter for the Biologic License Applications (BLA) for their new bone drug Denosumab (Prolia) for the treatment and prevention of postmenopausal osteoporosis.
Continue reading...FDA approves GSK’s Votrient (NYSE:GSK)
20 October 2009
Comments Off
It was a nice Monday morning for GSK when they made an announcement that the Food and Drug Administration has voted in the favor of their new cancer drug Votrient.
Continue reading...FDA approves Acorda’s MS drug (NASDAQ:ACOR)
16 October 2009
Comments Off
It was a bad news for Acorda Therapeutics when they heard the news that NASDAQ has halted their trading and shares of Acorda Therapeutics were 18 percent down on the stock market.
Continue reading...GlaxoSmithKline RNA Pact (NYSE:GSK)
14 October 2009
Comments Off
On early Monday morning GlaxoSmithKline has decided to pay upfront fees and milestone payments to the Dutch biotech company Prosensa. GSK has committed to pay the upfront fees of US$ 680 million to Prosensa for the package of four RNA programs aimed at DMD or also known as Duchenne Muscular Dystrophy.
Continue reading...Acorda shares sink (NASDAQ:ACOR)
12 October 2009
Comments Off
It was a not a good closing day for Acorda Therapeutics when shares of its company went down drastically after the negative review by the Food and Drug Administration panel.
Continue reading...Pfizer gets another setback (NYSE:PFE)
12 October 2009
Comments Off
Pfizer Inc announced one of the most shocking news on Friday that the conclusions of their experimental lung cancer drug were not definitive. The news was announced on a Friday afternoon after which the shares of Pfizer did went down for sometime but eventually at the end of the day the shares of Pfizer were [...]
Continue reading...OxiGENE Makes New Management Changes (NASDAQ:OXGN)
9 October 2009
Comments Off
Early Thursday morning, OxiGENE Inc came up with an announcement that its Chief Executive Officer, John A. Kollins has resigned from his position with the Company and also as a member of the Board of Directors in order to pursue other interests.
Continue reading...Acorda’s New Drug (NASDAQ:ACOR)
8 October 2009
Comments Off
Acorda Therapeutics is very excited and waiting anxiously for the review of their new drug Amaya by the Food and Drug Administration advisory committee. Acorda’s new Amaya drug is targeted for the treatment of multiple sclerosis and it will be reviewed by the FDA on October 14, 2009.
Continue reading...Genzyme Receives FDA Letter (NASDAQ:GENZ)
7 October 2009
Comments Off
Genzyme Corporation has announced that they have received a complete response letter from the Food and Drug Administration about the company’s supplemental New Drug Application for Clolar in patients suffering from acute myeloid leukemia or untreated older patients with AML. In the response letter to Genzyme Corporation, FDA has clearly mentioned that they need to [...]
Continue reading...Vertex Hep C Competitor (NASDAQ:VRTX)
6 October 2009
Comments Off
Competition in the biotech sector is always cut-throat and that is what makes this sector more dynamic than any other as the faith of the company lies directly in the hands of the researchers that come out with life saving drugs that can sweep the market by storm. Currently the hepatitis C drug called telaprevir [...]
Continue reading...
20 October 2009
Comments Off